• 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br ajp amjpathol org The


    920 - The American Journal of Pathology
    High miR-182 Solasodine in Low-Risk Prostate Cancer
    B.B. and L.N. conceived and designed the study, analyzed data, and wrote the manuscript; B.B., A.M.A., Z.R., and A.S. acquired and analyzed data; R.D. performed TMA scanning and assisted with inForm software analysis; P.H.G. provided advice on statistics and interpreted data; A.K.-B. provided the Outcome TMA; A.M. provided the Murphy TMA; the manuscript was reviewed and revised by all authors.
    Supplemental Data
    2. Lardas M, Liew M, van den Bergh RC, De Santis M, Bellmunt J, Van den Broeck T, Cornford P, Cumberbatch MG, Fossati N, Gross T, Henry AM, Bolla M, Briers E, Joniau S, Lam TB, Mason MD, Mottet N, van der Poel HG, Rouviere O, Schoots IG, Wiegel T, Willemse PM, Yuan CY, Bourke L: Quality of life outcomes after primary treatment for clinically localised prostate cancer: a systematic review. Eur Urol 2017, 72:869e885
    3. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll PR: The University of California, San Francisco cancer of the prostate risk assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005, 173:1938e1942
    4. Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP 3rd, Kawachi MH, Kim S, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Moses KA, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenkle P, Vickers AJ, Wake R, Shead DA, Freedman-Cass DA: NCCN guidelines insights: prostate cancer early detection, version 2.2016. J Natl Compr Canc Netw 2016, 14: 509e519
    5. Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, Ali A, Chen Y, Knezevic D, Maddala T, Lawrence HJ, Febbo PG, Srivastava S, Sesterhenn IA, McLeod DG: A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatec-tomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur Urol 2015, 68:123e131
    6. Freedland SJ, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, Younus A, Gutin A, Sangale Z, Lanchbury JS, Salama JK, Stone S: Prognostic utility of Solasodine progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys 2013, 86:848e853
    7. Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choeurng V, Feng FY, Dicker AP, Lallas CD, Gomella LG, Davicioni E, Karnes RJ: Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol 2015, 33:944e951
    8. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N: Widespread changes in protein synthesis induced by microRNAs. Nature 2008, 455:58e63
    10. Mihelich BL, Maranville JC, Nolley R, Peehl DM, Nonn L: Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort. PLoS One 2015, 10:e0124245
    12. Fabris L, Ceder Y, Chinnaiyan AM, Jenster GW, Sorensen KD, Tomlins S, Visakorpi T, Calin GA: The potential of microRNAs as prostate cancer biomarkers. Eur Urol 2016, 70:312e322
    13. Bonci D, Coppola V, Patrizii M, Addario A, Cannistraci A, Francescangeli F, Pecci R, Muto G, Collura D, Bedini R, Zeuner A, Valtieri M, Sentinelli S, Benassi MS, Gallucci M, Carlini P, Piccolo S, De Maria R: A microRNA code for prostate cancer metastasis. Oncogene 2016, 35:1180e1192
    15. Tsuchiyama K, Ito H, Taga M, Naganuma S, Oshinoya Y, Nagano K, Yokoyama O, Itoh H: Expression of micrornas associated with Gleason grading system in prostate cancer: mir-182-5p is a useful marker for high grade prostate cancer. Prostate 2013, 73:827e834
    16. Sun Y, Jia X, Hou L, Liu X: Screening of differently expressed miRNA and mRNA in prostate cancer by integrated analysis of transcription data. Urology 2016, 94:313.e1e313.e6
    17. Hirata H, Ueno K, Shahryari V, Deng G, Tanaka Y, Tabatabai ZL, Hinoda Y, Dahiya R: MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer. PLoS One 2013, 8:e55502
    19. Dambal S, Baumann B, McCray T, Williams L, Richards Z, Deaton R, Prins GS, Nonn L: The Mir-183 family cluster alters zinc homeostasis in benign prostate cells, organoids and prostate cancer xenografts. Sci Rep 2017, 7:7704
    20. Wang D, Lu G, Shao Y, Xu D: Mir-182 promotes prostate cancer progression through activating Wnt/Beta-catenin signal pathway. Biomed Pharmacother 2018, 99:334e339